Breaking News Instant updates and real-time market news.

BIIB

Biogen

$395.89 /

+109.83 (+38.39%)

16:41
06/07/21
06/07
16:41
06/07/21
16:41

Biogen upgraded to Neutral from Underperform at Baird

Baird analyst Brian Skorney upgraded Biogen to Neutral from Underperform with a price target of $382, up from $216.

  • 07

    Jun

BIIB Biogen
$395.89 /

+109.83 (+38.39%)

06/07/21 Raymond James
Raymond James upgrades Biogen to Market Perform, says 'dead wrong' on prediction
06/07/21 Raymond James
Biogen upgraded to Market Perform from Underperform at Raymond James
06/07/21 Cowen
Biogen upgraded to Outperform from Market Perform at Cowen
06/07/21 JMP Securities
Aducanumab accelerated approval positive for Athira, others, says JMP Securities

TODAY'S FREE FLY STORIES

Recommendations
JinkoSolar price target lowered to $51 from $58 at Roth Capital » 21:08
09/16/21
09/16
21:08
09/16/21
21:08
JKS

JinkoSolar

$46.96 /

-1.72 (-3.53%)

Roth Capital analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
JKS JinkoSolar
$46.96 /

-1.72 (-3.53%)

JKS JinkoSolar
$46.96 /

-1.72 (-3.53%)

10:33 Today GLJ Research
GLJ sees nearly 80% downside in JinkoSolar, cuts target to $10.70
08/13/21 GLJ Research
JinkoSolar shipment into U.S. stopped by customs, says GLJ Research
07/02/21 Goldman Sachs
JinkoSolar price target raised to $27 from $25 at Goldman Sachs
06/30/21 Roth Capital
JinkoSolar price target raised to $58 from $39 at Roth Capital
JKS JinkoSolar
$46.96 /

-1.72 (-3.53%)

JKS JinkoSolar
$46.96 /

-1.72 (-3.53%)

JKS JinkoSolar
$46.96 /

-1.72 (-3.53%)

Initiation
Pangaea Logistics initiated with a Buy at B. Riley » 21:05
09/16/21
09/16
21:05
09/16/21
21:05
PANL

Pangaea Logistics

$5.83 /

+0.26 (+4.67%)

B. Riley initiated…

B. Riley initiated coverage of Pangaea Logistics with a Buy rating and $7.50 price target.

ShowHide Related Items >><<
PANL Pangaea Logistics
$5.83 /

+0.26 (+4.67%)

PANL Pangaea Logistics
$5.83 /

+0.26 (+4.67%)

Hot Stocks
AeroVironment chairman sells 18K shares of common stock » 21:02
09/16/21
09/16
21:02
09/16/21
21:02
AVAV

AeroVironment

$87.29 /

-0.51 (-0.58%)

In a regulatory filing,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AVAV AeroVironment
$87.29 /

-0.51 (-0.58%)

AVAV AeroVironment
$87.29 /

-0.51 (-0.58%)

09/09/21 Canaccord
AeroVironment results stronger than expected, says Canaccord
09/03/21 Canaccord
AeroVironment price target raised to $88 from $84 at Canaccord
08/27/21 Imperial Capital
AeroVironment initiated with an In-Line at Imperial Capital
06/30/21 Canaccord
AeroVironment remains well supported by budget fundamentals, says Canaccord
AVAV AeroVironment
$87.29 /

-0.51 (-0.58%)

AVAV AeroVironment
$87.29 /

-0.51 (-0.58%)

Hot Stocks
Williams-Sonoma CEO sells 15K shares of common stock » 21:01
09/16/21
09/16
21:01
09/16/21
21:01
WSM

Williams-Sonoma

$188.52 /

+4.285 (+2.33%)

In a regulatory filing,…

In a regulatory filing, Williams-Sonoma disclosed that its CEO Laura Alber sold 15K shares of common stock on September 14th in a total transaction size of $2.67M, reducing her stake by about 3%.

ShowHide Related Items >><<
WSM Williams-Sonoma
$188.52 /

+4.285 (+2.33%)

WSM Williams-Sonoma
$188.52 /

+4.285 (+2.33%)

08/26/21 RBC Capital
Williams-Sonoma price target raised to $199 from $191 at RBC Capital
08/26/21 Wedbush
Williams-Sonoma price target raised to $220 from $200 at Wedbush
08/26/21 Loop Capital
Williams-Sonoma price target raised to $190 from $180 at Loop Capital
08/26/21 Credit Suisse
Williams-Sonoma price target raised to $155 from $144 at Credit Suisse
WSM Williams-Sonoma
$188.52 /

+4.285 (+2.33%)

WSM Williams-Sonoma
$188.52 /

+4.285 (+2.33%)

WSM Williams-Sonoma
$188.52 /

+4.285 (+2.33%)

Hot Stocks
Arctic Vision, Eyenovia to partner on MydCombi commercialization in China, Korea » 20:18
09/16/21
09/16
20:18
09/16/21
20:18
EYEN

Eyenovia

$4.45 /

+ (+0.00%)

Arctic Vision announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EYEN Eyenovia
$4.45 /

+ (+0.00%)

EYEN Eyenovia
$4.45 /

+ (+0.00%)

04/01/21 H.C. Wainwright
Eyenovia price target raised to $8 from $6 at H.C. Wainwright
03/01/21 Northland
Eyenovia initiated with an Outperform at Northland
12/30/20 H.C. Wainwright
H.C. Wainwright reiterates $6 target on Eyenovia after new drug submission
10/23/20 H.C. Wainwright
Eyenovia price target lowered to $6 from $7 at H.C. Wainwright
EYEN Eyenovia
$4.45 /

+ (+0.00%)

Initiation
Twilio assumed with a Buy at Summit Insights » 20:03
09/16/21
09/16
20:03
09/16/21
20:03
TWLO

Twilio

$345.87 /

+4.025 (+1.18%)

Summit Insights analyst…

Summit Insights analyst Srini Nandury assumed coverage of Twilio with a Buy rating and $450 price target. As the leader in next generation CPaaS, or Communication Platform as a Service, the company should grow north of 30% until the end of at least 2025, the analyst tells investors in a research note. Nandury adds that Twilio deserves a premium multiple given the prospect of continued high growth, the potential for margin expansion, solid execution, industry leadership, secular growth trends, and a deep competitive moat.

ShowHide Related Items >><<
TWLO Twilio
$345.87 /

+4.025 (+1.18%)

TWLO Twilio
$345.87 /

+4.025 (+1.18%)

07/30/21 Baird
Twilio price target raised to $450 from $430 at Baird
07/30/21 Mizuho
Twilio price target raised to $430 from $400 at Mizuho
07/30/21 RBC Capital
Twilio price target raised to $450 from $415 at RBC Capital
07/30/21 Jefferies
Twilio price target raised to $450 from $415 at Jefferies
TWLO Twilio
$345.87 /

+4.025 (+1.18%)

  • 19
    Feb
TWLO Twilio
$345.87 /

+4.025 (+1.18%)

TWLO Twilio
$345.87 /

+4.025 (+1.18%)

TWLO Twilio
$345.87 /

+4.025 (+1.18%)

Downgrade
Ferrari cut to Neutral at Exane BNP Paribas on slow cyclical recovery » 20:01
09/16/21
09/16
20:01
09/16/21
20:01
RACE

Ferrari

$218.94 /

-2.76 (-1.24%)

As previously reported,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RACE Ferrari
$218.94 /

-2.76 (-1.24%)

RACE Ferrari
$218.94 /

-2.76 (-1.24%)

12:14 Today Exane BNP Paribas
Ferrari downgraded to Neutral from Outperform at Exane BNP Paribas
09/15/21 BofA
BofA calls Lucid the 'Tesla/Ferrari of new EV automakers,' starts at Buy
09/09/21 Oddo BHF
Ferrari initiated with an Outperform at Oddo BHF
07/16/21 BofA
Ferrari price target lowered to $281 from $287 at BofA
RACE Ferrari
$218.94 /

-2.76 (-1.24%)

RACE Ferrari
$218.94 /

-2.76 (-1.24%)

RACE Ferrari
$218.94 /

-2.76 (-1.24%)

Downgrade
Autoliv downgraded to Underperform from Neutral at Exane BNP Paribas » 19:57
09/16/21
09/16
19:57
09/16/21
19:57
ALV

Autoliv

$84.36 /

-3.8 (-4.31%)

Exane BNP Paribas analyst…

Exane BNP Paribas analyst Stuart Pearson downgraded Autoliv to Underperform from Neutral with an $87 price target as part of a broader research note on Automotive. The analyst preview the "shape of the cycle ahead", anticipating supply side constraints, disruption from fractured supply-logistics, and a bottleneck of battery raw materials. Peason adds that 2021 should be the "slowest first year of cyclical recovery in modern history", also reducing his 2021-2023 volume estimates by 4% to 10M units.

ShowHide Related Items >><<
ALV Autoliv
$84.36 /

-3.8 (-4.31%)

ALV Autoliv
$84.36 /

-3.8 (-4.31%)

12:06 Today Exane BNP Paribas
Autoliv downgraded to Underperform from Neutral at Exane BNP Paribas
07/19/21 Deutsche Bank
Autoliv price target lowered to $96 from $101 at Deutsche Bank
07/19/21 Mizuho
Autoliv price target lowered to $112 from $115 at Mizuho
07/19/21 RBC Capital
Autoliv price target lowered to $104 from $117 at RBC Capital
ALV Autoliv
$84.36 /

-3.8 (-4.31%)

ALV Autoliv
$84.36 /

-3.8 (-4.31%)

Upgrade
Lagardere upgraded to Neutral from Underperform at Exane BNP Paribas » 19:51
09/16/21
09/16
19:51
09/16/21
19:51
LGDDF

Lagardere

$26.49 /

+ (+0.00%)

, VIVHY

Vivendi

$37.47 /

+0.17 (+0.46%)

Exane BNP Paribas analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VIVHY Vivendi
$37.47 /

+0.17 (+0.46%)

LGDDF Lagardere
$26.49 /

+ (+0.00%)

07/28/21 Barclays
Lagardere price target raised to EUR 25.50 from EUR 24.50 at Barclays
07/27/21 Societe Generale
Lagardere upgraded to Buy from Hold at Societe Generale
05/06/21 Oddo BHF
Lagardere upgraded to Neutral from Underperform at Oddo BHF
03/01/21 Barclays
Lagardere price target raised to EUR 24.50 from EUR 20 at Barclays
VIVHY Vivendi
$37.47 /

+0.17 (+0.46%)

08/26/21 UBS
Vivendi price target raised to EUR 41 from EUR 38 at UBS
08/26/21 JPMorgan
Vivendi price target raised to EUR 45 from EUR 44 at JPMorgan
08/26/21 Barclays
Vivendi upgraded to Overweight from Equal Weight at Barclays
07/29/21 Credit Suisse
Vivendi price target raised to EUR 33.60 from EUR 32.20 at Credit Suisse
VIVHY Vivendi
$37.47 /

+0.17 (+0.46%)

VIVHY Vivendi
$37.47 /

+0.17 (+0.46%)

Hot Stocks
Novavax to participate in Oxford Com-COV3 study » 19:04
09/16/21
09/16
19:04
09/16/21
19:04
NVAX

Novavax

$237.14 /

+5.03 (+2.17%)

Novavax announced its…

Novavax announced its participation in a newly expanded Phase 2 clinical trial called Comparing COVID-19 Vaccine Schedule Combinations - Stage 3, led by the University of Oxford and funded by the UK Vaccines Taskforce and the National Institute for Health Research. Novavax' recombinant nanoparticle COVID-19 vaccine candidate, NVX-CoV2373, is one of the three COVID-19 vaccines that will be studied in adolescents to evaluate the potential for combined regimens that mix vaccines from different manufacturers to achieve immune protection against COVID-19. "Expanding our understanding of how different COVID-19 vaccines can be used to implement flexible vaccine programs across all age groups will be vital to ultimately controlling the pandemic," said Gregory M. Glenn, M.D., President of Research and Development, Novavax. "A mixed vaccination series could offer the potential to maximize the use of existing vaccine supply, increase the total number of individuals who can ultimately be vaccinated and accelerate rapid and equitable access across the globe." Com-COV3 will include at least 360 adolescents 12-16 years of age. Volunteers will receive an authorized vaccine as a first dose and then at least 8 weeks later will receive one of three different vaccines as a second dose. All participants will be randomly allocated at the time of the second dose to receive either a full dose or half dose of the same vaccine given for the first dose, a full dose of the Novavax vaccine or a half dose of a different authorized vaccine. The research will compare the immune system responses from those who receive a heterologous regimen to those who receive a homologous regimen.

ShowHide Related Items >><<
NVAX Novavax
$237.14 /

+5.03 (+2.17%)

NVAX Novavax
$237.14 /

+5.03 (+2.17%)

09/08/21 Cantor Fitzgerald
Novavax combo vaccine could have 'differentiating' value, says Cantor Fitzgerald
08/30/21 B. Riley
Novavax is leader in making Covid-flu combination candidate, says B. Riley
08/04/21 Cantor Fitzgerald
Novavax EU deal suggests bottlenecks have been resolved, says Cantor Fitzgerald
06/15/21 Cantor Fitzgerald
Novavax price target raised to $272 from $217 at Cantor Fitzgerald
NVAX Novavax
$237.14 /

+5.03 (+2.17%)

NVAX Novavax
$237.14 /

+5.03 (+2.17%)

NVAX Novavax
$237.14 /

+5.03 (+2.17%)

NVAX Novavax
$237.14 /

+5.03 (+2.17%)

On The Fly
Fly Intel: After-Hours Movers » 19:03
09/16/21
09/16
19:03
09/16/21
19:03
ABCL

AbCellera

$19.80 /

+1.03 (+5.49%)

, FANG

Diamondback Energy

$79.98 /

-1.63 (-2.00%)

, AGEN

Agenus

$5.57 /

+0.19 (+3.53%)

, CVGW

Calavo Growers

$36.64 /

+1.72 (+4.93%)

, OPAD

Offerpad Solutions

$20.17 /

+7.395 (+57.89%)

, IRNT

IronNet

$41.31 /

+9.255 (+28.87%)

, USNA

Usana

$87.51 /

+0.085 (+0.10%)

, X

U.S. Steel

$25.40 /

-0.27 (-1.05%)

Check out this evening's…

ShowHide Related Items >><<
X U.S. Steel
$25.40 /

-0.27 (-1.05%)

USNA Usana
$87.51 /

+0.085 (+0.10%)

OPAD Offerpad Solutions
$20.17 /

+7.395 (+57.89%)

IRNT IronNet
$41.31 /

+9.255 (+28.87%)

FANG Diamondback Energy
$79.98 /

-1.63 (-2.00%)

CVGW Calavo Growers
$36.64 /

+1.72 (+4.93%)

AGEN Agenus
$5.57 /

+0.19 (+3.53%)

ABCL AbCellera
$19.80 /

+1.03 (+5.49%)

ABCL AbCellera
$19.80 /

+1.03 (+5.49%)

06/11/21 BMO Capital
AbCellera coverage transferred at BMO Capital
03/30/21 SVB Leerink
AbCellera price target lowered to $45 from $52 at SVB Leerink
03/24/21 BMO Capital
AbCellera price target lowered to $59 from $61 at BMO Capital
02/08/21 SVB Leerink
AbCellera price target raised to $52 from $45 at SVB Leerink
FANG Diamondback Energy
$79.98 /

-1.63 (-2.00%)

09/15/21 Truist
Diamondback Energy price target raised to $130 from $122 at Truist
07/22/21 Piper Sandler
Diamondback Energy price target raised to $112 from $102 at Piper Sandler
07/15/21 Mizuho
Diamondback Energy price target raised to $131 from $120 at Mizuho
07/07/21 Wells Fargo
Diamondback Energy price target raised to $101 from $90 at Wells Fargo
AGEN Agenus
$5.57 /

+0.19 (+3.53%)

09/07/21 B. Riley
Agenus price target raised to $12 from $11 at B. Riley
06/28/21 B. Riley
Agenus price target raised to $11 from $8 at B. Riley
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
09/22/20 B. Riley
B. Riley FBR calls Agenus 'hidden gem' amidst ESMO data releases
CVGW Calavo Growers
$36.64 /

+1.72 (+4.93%)

09/09/21 Lake Street
Calavo Growers price target lowered to $60 from $70 at Lake Street
08/05/21 Lake Street
Calavo Growers price target lowered to $70 from $85 at Lake Street
06/04/21 Lake Street
Calavo Growers assumed with a Buy at Lake Street
03/11/21 Lake Street
Calavo Growers price target raised to $73 from $62 at Lake Street
OPAD Offerpad Solutions
$20.17 /

+7.395 (+57.89%)

IRNT IronNet
$41.31 /

+9.255 (+28.87%)

USNA Usana
$87.51 /

+0.085 (+0.10%)

02/10/21 Roth Capital
Usana price target raised to $126 from $107 at Roth Capital
12/17/20 Roth Capital
Usana initiated with a Buy at Roth Capital
X U.S. Steel
$25.40 /

-0.27 (-1.05%)

09/15/21 Deutsche Bank
U.S. Steel price target raised to $50 from $38 at Deutsche Bank
07/07/21 Credit Suisse
Steel demand booming in the U.S., says Credit Suisse
07/01/21 Deutsche Bank
U.S. Steel price target raised to $38 from $30 at Deutsche Bank
06/16/21
Fly Intel: Top five analyst downgrades
X U.S. Steel
$25.40 /

-0.27 (-1.05%)

USNA Usana
$87.51 /

+0.085 (+0.10%)

FANG Diamondback Energy
$79.98 /

-1.63 (-2.00%)

CVGW Calavo Growers
$36.64 /

+1.72 (+4.93%)

AGEN Agenus
$5.57 /

+0.19 (+3.53%)

ABCL AbCellera
$19.80 /

+1.03 (+5.49%)

  • 03
    Feb
  • 11
    Dec
X U.S. Steel
$25.40 /

-0.27 (-1.05%)

X U.S. Steel
$25.40 /

-0.27 (-1.05%)

IRNT IronNet
$41.31 /

+9.255 (+28.87%)

CVGW Calavo Growers
$36.64 /

+1.72 (+4.93%)

AGEN Agenus
$5.57 /

+0.19 (+3.53%)

ABCL AbCellera
$19.80 /

+1.03 (+5.49%)

X U.S. Steel
$25.40 /

-0.27 (-1.05%)

OPAD Offerpad Solutions
$20.17 /

+7.395 (+57.89%)

IRNT IronNet
$41.31 /

+9.255 (+28.87%)

FANG Diamondback Energy
$79.98 /

-1.63 (-2.00%)

AGEN Agenus
$5.57 /

+0.19 (+3.53%)

ABCL AbCellera
$19.80 /

+1.03 (+5.49%)

Hot Stocks
Agenus to present data on combination of Balstilimab and Zalifrelimab at ESMO » 18:33
09/16/21
09/16
18:33
09/16/21
18:33
AGEN

Agenus

$5.57 /

+0.19 (+3.53%)

Agenus presented final…

Agenus presented final results from the Bal/Zal combination study at the European Society for Medical Oncology Virtual Conference 2021 in an abstract titled Balstilimab in combination with zalifrelimab: final results from a Phase 2 study in patients with recurrent/metastatic cervical cancer... The Phase 2 trial was conducted in 155 patients with recurrent/metastatic cervical cancer which has limited effective treatment options and disproportionately affects younger women. In the 125 evaluable patients, the objective response rate in all patients was 26%, with 9% of patients achieving a complete response, and 17% of patients achieving a partial response. The median duration of response was not reached after a 19.4-month median follow-up. Notably, responses were also observed in the PD-L1 negative and adenocarcinoma populations, with 9% of both patient groups achieving an ORR. Based on these observations, we predict more than half of the patients to be alive beyond 12 months. The Bal/Zal combination continued to show no unexpected toxicities and no new safety signals were identified. Steven O'Day, MD, Chief Medical Officer of Agenus, stated: "With a median follow-up of almost 2 years, the Bal/Zal combination showed high response rates, durable clinical activity, and promising overall survival results. Furthermore, later this year we expect to present new data on our next-generation CTLA-4 inhibitor AGEN1181, which we expect to further define the positive role this combination strategy could have in addressing unmet needs for cancer patients."

ShowHide Related Items >><<
AGEN Agenus
$5.57 /

+0.19 (+3.53%)

AGEN Agenus
$5.57 /

+0.19 (+3.53%)

09/07/21 B. Riley
Agenus price target raised to $12 from $11 at B. Riley
06/28/21 B. Riley
Agenus price target raised to $11 from $8 at B. Riley
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
09/22/20 B. Riley
B. Riley FBR calls Agenus 'hidden gem' amidst ESMO data releases
AGEN Agenus
$5.57 /

+0.19 (+3.53%)

AGEN Agenus
$5.57 /

+0.19 (+3.53%)

AGEN Agenus
$5.57 /

+0.19 (+3.53%)

Hot Stocks
Sight Sciences files patent infringement lawsuit against Ivantis » 18:30
09/16/21
09/16
18:30
09/16/21
18:30
SGHT

Sight Sciences

$28.33 /

-0.47 (-1.63%)

Sight Sciences announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SGHT Sight Sciences
$28.33 /

-0.47 (-1.63%)

SGHT Sight Sciences
$28.33 /

-0.47 (-1.63%)

09/15/21 Piper Sandler
Piper says Glaukos patent settlement doesn't ease reimbursement challenges
08/09/21
Fly Intel: Top five analyst initiations
08/09/21 BofA
Sight Sciences initiated with a Buy at BofA
08/09/21 Citi
Sight Sciences initiated with a Buy at Citi
  • 15
    Jul
SGHT Sight Sciences
$28.33 /

-0.47 (-1.63%)

Hot Stocks
Coherus, Junshi to present PFS, OS results from JUPITER-06 » 18:29
09/16/21
09/16
18:29
09/16/21
18:29
CHRS

Coherus Biosciences

$16.04 /

+0.29 (+1.84%)

Coherus Biosciences and…

Coherus Biosciences and Shanghai Junshi Biosciences announced positive interim results from the pivotal study "JUPITER-06," a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab in combination with chemotherapy as a first-line therapy for patients with advanced or metastatic esophageal squamous cell carcinoma. The study met the co-primary endpoints with statistically significant and clinically meaningful improvements in progression free survival and overall survival for patients treated with the toripalimab and chemotherapy combination compared to chemotherapy alone. The results will be summarized by Dr. Feng Wang, Professor at Sun Yat-sen University Cancer Center, Guangzhou, in a mini-oral session during the ESMO Congress 2021 on Friday, September 17, 2021 at 12:05 pm Eastern Time. The abstract is now available on the ESMO website. "The findings of this interim analysis provide strong evidence that the addition of toripalimab to chemotherapy as a first-line treatment for advanced or metastatic ESCC patients has superior PFS and OS than chemotherapy alone," said Dr. Wang. "We look forward to updated analyses of overall survival of the JUPITER-06 study in the future and believe that these results will build a strong argument to support the use of toripalimab in combination with chemotherapy as a new standard first-line treatment in patients with advanced or metastatic ESCC." "A strong and consistent efficacy and safety profile is emerging for toripalimab across multiple tumor types as data read out from pivotal clinical trials in melanoma, nasopharyngeal carcinoma, urothelial cancer, lung cancer and now also esophageal squamous cell carcinoma," said Dr. Patricia Keegan, Chief Medical Officer of Junshi Biosciences. "We believe toripalimab could be a potential new treatment choice where patients truly need better options. We will collaborate with Coherus to advance a BLA supplement for ESCC to make toripalimab available as quickly as possible for these patients in the U.S."

ShowHide Related Items >><<
CHRS Coherus Biosciences
$16.04 /

+0.29 (+1.84%)

CHRS Coherus Biosciences
$16.04 /

+0.29 (+1.84%)

07/23/21 H.C. Wainwright
Coherus Biosciences price target raised to $36 from $26 at H.C. Wainwright
05/17/21 Barclays
Coherus Biosciences price target lowered to $24 from $28 at Barclays
05/07/21 H.C. Wainwright
Coherus Biosciences price target lowered to $26 from $28 at H.C. Wainwright
02/25/21 Citi
Coherus Biosciences price target lowered to $27 from $30 at Citi
CHRS Coherus Biosciences
$16.04 /

+0.29 (+1.84%)

Hot Stocks
Dixie Group sells its AtlasMasland commercial business for $27.5M » 18:07
09/16/21
09/16
18:07
09/16/21
18:07
DXYN

Dixie Group

$5.39 /

+0.08 (+1.51%)

Dixie Group announced the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DXYN Dixie Group
$5.39 /

+0.08 (+1.51%)

DXYN Dixie Group
$5.39 /

+0.08 (+1.51%)

Hot Stocks
McAfee CFO sells 29,630 class A shares » 18:05
09/16/21
09/16
18:05
09/16/21
18:05
MCFE

McAfee

$21.78 /

+0.58 (+2.74%)

In a regulatory filing,…

In a regulatory filing, McAfee CFO Venkat Bhamidipati disclosed the sale of 29,630 class A common shares of the company on September 14 at a price of $21.7125 per share.

ShowHide Related Items >><<
MCFE McAfee
$21.78 /

+0.58 (+2.74%)

MCFE McAfee
$21.78 /

+0.58 (+2.74%)

09/13/21 Morgan Stanley
McAfee pullback a 'strong buying opportunity,' says Morgan Stanley
09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 UBS
McAfee resumed to Neutral from Buy at UBS
06/17/21 Mizuho
McAfee price target raised to $30 from $28 at Mizuho
MCFE McAfee
$21.78 /

+0.58 (+2.74%)

  • 10
    Sep
  • 22
    Oct
MCFE McAfee
$21.78 /

+0.58 (+2.74%)

MCFE McAfee
$21.78 /

+0.58 (+2.74%)

Hot Stocks
Amerant Bancorp names Kristy Amaro as Chief Diversity & Inclusion Officer » 18:04
09/16/21
09/16
18:04
09/16/21
18:04
AMTB

Amerant Bancorp

$24.59 /

-0.73 (-2.88%)

Amerant Bancorp announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AMTB Amerant Bancorp
$24.59 /

-0.73 (-2.88%)

AMTB Amerant Bancorp
$24.59 /

-0.73 (-2.88%)

08/30/21
Fly Intel: Top five analyst upgrades
08/30/21 Piper Sandler
Amerant Bancorp upgraded to Overweight from Neutral at Piper Sandler
06/02/21 Stephens
Amerant Bancorp initiated with an Equal Weight at Stephens
05/17/21 Truist
Amerant Bancorp price target raised to $25 from $18 at Truist
AMTB Amerant Bancorp
$24.59 /

-0.73 (-2.88%)

Hot Stocks
McAfee CEO Leav sells nearly 130,000 class A shares » 18:04
09/16/21
09/16
18:04
09/16/21
18:04
MCFE

McAfee

$21.78 /

+0.58 (+2.74%)

In a regulatory filing,…

In a regulatory filing, McAfee president and CEO Peter Leav disclosed the sale of 129,591 class A common shares of the company on September 14 at a price of $21.7125 per share.

ShowHide Related Items >><<
MCFE McAfee
$21.78 /

+0.58 (+2.74%)

MCFE McAfee
$21.78 /

+0.58 (+2.74%)

09/13/21 Morgan Stanley
McAfee pullback a 'strong buying opportunity,' says Morgan Stanley
09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 UBS
McAfee resumed to Neutral from Buy at UBS
06/17/21 Mizuho
McAfee price target raised to $30 from $28 at Mizuho
MCFE McAfee
$21.78 /

+0.58 (+2.74%)

  • 10
    Sep
  • 22
    Oct
MCFE McAfee
$21.78 /

+0.58 (+2.74%)

MCFE McAfee
$21.78 /

+0.58 (+2.74%)

Periodicals
Invesco in talks over tie-up with State Street's asset management unit, WSJ says » 18:00
09/16/21
09/16
18:00
09/16/21
18:00
STT

State Street

$87.03 /

-0.9 (-1.02%)

, IVZ

Invesco

$24.88 /

-0.67 (-2.62%)

Invesco (IVZ) is in…

Invesco (IVZ) is in discussions to combine with State Street's (STT) asset management unit, the Wall Street Journal's Justin Baer and Cara Lombardo report, citing people familiar with the matter. An agreement is not imminent, and talks may not result in a deal, the authors note. Reference Link

ShowHide Related Items >><<
STT State Street
$87.03 /

-0.9 (-1.02%)

IVZ Invesco
$24.88 /

-0.67 (-2.62%)

STT State Street
$87.03 /

-0.9 (-1.02%)

09/09/21 JPMorgan
JPMorgan expects 'sizable equity issue' from State Street after deal
09/08/21 Jefferies
State Street pullback on BBH deal a buying opportunity, says Jefferies
09/08/21 Morgan Stanley
Brown Brothers Harriman to make State Street more efficient, says Morgan Stanley
07/19/21 Deutsche Bank
State Street price target raised to $105 from $104 at Deutsche Bank
IVZ Invesco
$24.88 /

-0.67 (-2.62%)

07/12/21 Deutsche Bank
Invesco price target raised to $35 from $33 at Deutsche Bank
07/12/21 Citi
Invesco upgraded to Buy from Neutral at Citi
04/09/21 Deutsche Bank
Invesco price target raised to $31 from $28 at Deutsche Bank
01/28/21
Fly Intel: Top five analyst upgrades
STT State Street
$87.03 /

-0.9 (-1.02%)

IVZ Invesco
$24.88 /

-0.67 (-2.62%)

  • 10
    Sep
STT State Street
$87.03 /

-0.9 (-1.02%)

STT State Street
$87.03 /

-0.9 (-1.02%)

STT State Street
$87.03 /

-0.9 (-1.02%)

IVZ Invesco
$24.88 /

-0.67 (-2.62%)

Conference/Events
FDA Pediatric Advisory Committee to hold a meeting » 17:40
09/16/21
09/16
17:40
09/16/21
17:40

The Committee discusses…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Conference/Events
Yum China to hold virtual investor day » 17:38
09/16/21
09/16
17:38
09/16/21
17:38
YUMC

Yum China

$55.68 /

-1.915 (-3.33%)

Virtual Investor Day to…

Virtual Investor Day to be held on September 22 at 8 pm. Webcast Link

ShowHide Related Items >><<
YUMC Yum China
$55.68 /

-1.915 (-3.33%)

YUMC Yum China
$55.68 /

-1.915 (-3.33%)

09/15/21 Macquarie
Macquarie downgrades Yum China to sell on 'bumpy' sales recovery
09/15/21 Macquarie
Yum China downgraded to Underperform from Neutral at Macquarie
07/07/21 Goldman Sachs
Yum China price target raised to $77 from $74 at Goldman Sachs
04/29/21 RBC Capital
Yum China price target raised to $123 from $112 at RBC Capital
YUMC Yum China
$55.68 /

-1.915 (-3.33%)

YUMC Yum China
$55.68 /

-1.915 (-3.33%)

YUMC Yum China
$55.68 /

-1.915 (-3.33%)

Hot Stocks
Ballard Power launches FCmove product for buses and trucks » 17:31
09/16/21
09/16
17:31
09/16/21
17:31
BLDP

Ballard Power

$15.14 /

-0.035 (-0.23%)

The company states:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BLDP Ballard Power
$15.14 /

-0.035 (-0.23%)

BLDP Ballard Power
$15.14 /

-0.035 (-0.23%)

09/13/21 Eight Capital
Ballard Power initiated with a Neutral at Eight Capital
08/31/21 Wolfe Research
Ballard Power initiated with an Underperform at Wolfe Research
05/05/21 BMO Capital
Ballard Power price target lowered to $23 from $35 at BMO Capital
05/05/21 B. Riley
Ballard Power price target lowered to $26 from $30 at B. Riley
BLDP Ballard Power
$15.14 /

-0.035 (-0.23%)

  • 10
    Mar
  • 10
    Feb
  • 24
    Nov
BLDP Ballard Power
$15.14 /

-0.035 (-0.23%)

BLDP Ballard Power
$15.14 /

-0.035 (-0.23%)

Conference/Events
Sprout Social to hold virtual investor day » 17:31
09/16/21
09/16
17:31
09/16/21
17:31
SPT

Sprout Social

$135.29 /

+1.77 (+1.33%)

Virtual Investor Day to…

Virtual Investor Day to be held on September 22 at 10 am. Webcast Link

ShowHide Related Items >><<
SPT Sprout Social
$135.29 /

+1.77 (+1.33%)

09/07/21 Stifel
Sprout Social price target raised to $135 from $105 at Stifel
08/04/21 Canaccord
Sprout Social price target raised to $100 from $77 at Canaccord
07/23/21 Barclays
Sprout Social price target raised to $106 from $77 at Barclays
07/16/21 Stifel
Sprout Social price target raised to $95 from $85 at Stifel
SPT Sprout Social
$135.29 /

+1.77 (+1.33%)

SPT Sprout Social
$135.29 /

+1.77 (+1.33%)

Hot Stocks
Methanex approves 5% share repurchase program » 17:29
09/16/21
09/16
17:29
09/16/21
17:29
MEOH

Methanex

$41.63 /

+0.64 (+1.56%)

Methanex has approved a…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MEOH Methanex
$41.63 /

+0.64 (+1.56%)

MEOH Methanex
$41.63 /

+0.64 (+1.56%)

09/13/21 Piper Sandler
Methanex initiated with a Neutral at Piper Sandler
09/07/21 Barclays
Methanex upgraded to Overweight from Equal Weight at Barclays
09/01/21 RBC Capital
Methanex to generate strong cash flows in 2021-22, says RBC Capital
07/19/21 TD Securities
Methanex price target raised to $54 from $51 at TD Securities
MEOH Methanex
$41.63 /

+0.64 (+1.56%)

Hot Stocks
ShotSpotter CFO Stewart purchases 5K shares of company stock » 17:27
09/16/21
09/16
17:27
09/16/21
17:27
SSTI

ShotSpotter

$34.83 /

-0.19 (-0.54%)

ShotSpotter CFO Alan…

ShotSpotter CFO Alan Stewart disclosed in a filing that he had purchased 5,000 shares of company stock at $34.74 per share between September 14 and September 15, for a total transaction value of $173,716.

ShowHide Related Items >><<
SSTI ShotSpotter
$34.83 /

-0.19 (-0.54%)

SSTI ShotSpotter
$34.83 /

-0.19 (-0.54%)

08/11/21 Roth Capital
ShotSpotter price target raised to $60 from $53 at Roth Capital
06/21/21 Craig-Hallum
ShotSpotter price target raised to $49 from $45 at Craig-Hallum
05/12/21 Craig-Hallum
ShotSpotter upgraded to Buy from Hold at Craig-Hallum
03/31/21 Craig-Hallum
ShotSpotter price target lowered to $40 from $45 at Craig-Hallum
SSTI ShotSpotter
$34.83 /

-0.19 (-0.54%)

SSTI ShotSpotter
$34.83 /

-0.19 (-0.54%)

SSTI ShotSpotter
$34.83 /

-0.19 (-0.54%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.